What Is Data-Dependent Acquisition (DDA) in Proteomics?
-
Standardized Sample Preparation Workflows: From sample lysis and protein extraction to enzymatic digestion and sample loading, the end-to-end process is tightly controlled, thereby substantially improving peptide-level consistency across runs.
-
Optimized Dynamic Exclusion Strategies: By refining the instrument’s dynamic exclusion (i.e., exclusion time window) settings, repeated MS/MS sampling of high-abundance peptides is reduced, improving the effective sampling rate for lower-abundance signals.
-
Integrated Advanced Database Searching: Mainstream search engines, including MaxQuant, PEAKS, and SpectroMine, are integrated to improve peptide identification coverage and confidence.
-
High-End Platform Support: High-resolution MS platforms such as the Orbitrap Exploris 480 and Q Exactive HF-X are employed to balance spectral quality with acquisition speed.
-
Extendable to DIA/PRM Analysis: Combined DDA+DIA strategies are supported, enabling an end-to-end research workflow spanning discovery through verification.
In contemporary life science research, proteomics is advancing basic research, mechanistic investigations of disease, and biomarker discovery at an unprecedented pace. Among proteomic data acquisition strategies, data-dependent acquisition (Data-Dependent Acquisition, DDA) was one of the earliest mass spectrometry (MS)-based approaches to achieve broad adoption. DDA not only remains central to protein identification, but also underpins many advanced methodologies in current use (e.g., DIA and PRM).
Principle of DDA
As implied by its name, DDA is an acquisition strategy in which subsequent scans are triggered by information acquired in preceding scans. Here, data primarily refers to the precursor ion signals observed in the MS1 survey scan, i.e., the peptide ion features detected across the full MS1 spectrum. In a typical DDA workflow, the instrument first performs an MS1 scan to measure the mass-to-charge ratios (m/z) and relative abundances of detectable peptide ions in a complex sample. The control software then applies a predefined selection rule, most commonly an intensity-ranked “Top N” scheme (e.g., Top10 or Top20), to sequentially choose the most abundant precursor ions for fragmentation. The selected precursors are isolated and fragmented (commonly by HCD or CID), producing corresponding MS/MS (MS2) spectra. These MS/MS spectra capture fragment-ion information generated upon peptide dissociation; database searching can then be used to infer peptide sequences and, subsequently, to achieve protein identification.
Technical Advantages and Limitations of DDA
1. Technical Advantages
(1) Highly Specific Fragmentation
In DDA, precursor ions are stringently selected prior to MS2 acquisition and are typically isolated within a defined m/z isolation window, which improves MS/MS spectral quality and supports more accurate peptide identification.
(2) Supports Classical Database Searching
DDA produces well-structured MS/MS datasets that are readily compatible with established search algorithms and pipelines, including SEQUEST, Mascot, and Andromeda (MaxQuant), and thus serves as a standard input format for widely used proteomic data analysis workflows.
(3) High-Quality Spectra Output
Because MS/MS acquisition is preferentially triggered for higher-intensity precursors, the resulting MS/MS spectra often exhibit lower background interference, facilitating confident interpretation of peptide fragmentation patterns.
(4) High Acquisition Efficiency
For studies with clearly defined objectives or relatively simple sample complexity, DDA can rapidly capture key protein information, thereby reducing experimental time and cost.
2. Limitations
Nevertheless, as proteomics increasingly demands deeper proteome coverage and higher quantitative accuracy, several inherent limitations of DDA have become more apparent:
(1) Preference for High-Abundance Proteins
Because DDA prioritizes high-intensity precursor ions for MS2 acquisition, low-abundance proteins (e.g., transcription factors and cytokines) are more likely to be undersampled or missed, which can compromise overall proteome coverage.
(2) High Run-to-Run Variability
Across different samples or batches, the set of precursors selected for MS2 is not fully consistent, leading to reduced reproducibility in peptide/protein identification.
(3) Frequent Missing Values
In large-cohort studies, certain peptides may not be selected for MS/MS in some samples, resulting in missing identifications and, consequently, missing quantitative values in downstream analyses.
(4) Instrument Speed Constraints
Even on high-end MS platforms, only a limited number of MS2 scans can be acquired within a given time window, making comprehensive sampling of all analytes in complex mixtures challenging.
These limitations have motivated the development of alternative strategies, such as data-independent acquisition (DIA). Importantly, however, interpretation of DIA data often continues to rely on high-quality reference libraries generated using DDA. Thus, even in the DIA era, DDA has not been displaced; instead, the two approaches are frequently used in a synergistic and complementary manner.
DDA Solutions of MtoZ Biolabs
As a company specializing in proteomics and mass spectrometry services, MtoZ Biolabs has accumulated extensive experience and technical strengths in DDA-based data acquisition and analysis. By balancing standardized workflows with customized service options, we aim to help researchers obtain more stable and reliable proteomic datasets.
Our DDA technical highlights include:
Although proteomics is increasingly characterized by full-scan quantitative strategies represented by DIA, DDA, one of the earliest core acquisition modes in MS-based omics, continues to occupy an irreplaceable position. Whether for novel protein discovery, spectral library construction, or exploratory studies, DDA remains a primary choice for high-quality protein identification. MtoZ Biolabs not only continues to refine DDA workflows, but also actively explores the integration and optimization of DDA with emerging approaches (e.g., DIA, AI-assisted searching, and machine learning-based spectral prediction), with the goal of delivering proteomics solutions that are most appropriate, reliable, and data-informative for researchers.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
